371 related articles for article (PubMed ID: 33985973)
1. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.
Martinez RS; Salji MJ; Rushworth L; Ntala C; Rodriguez Blanco G; Hedley A; Clark W; Peixoto P; Hervouet E; Renaude E; Kung SHY; Galbraith LCA; Nixon C; Lilla S; MacKay GM; Fazli L; Gaughan L; Sumpton D; Gleave ME; Zanivan S; Blomme A; Leung HY
Cancer Res; 2021 Jul; 81(13):3664-3678. PubMed ID: 33985973
[TBL] [Abstract][Full Text] [Related]
2. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
4. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract][Full Text] [Related]
5. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer.
Gordon JA; Noble JW; Midha A; Derakhshan F; Wang G; Adomat HH; Tomlinson Guns ES; Lin YY; Ren S; Collins CC; Nelson PS; Morrissey C; Wasan KM; Cox ME
Cancer Res; 2019 Jul; 79(13):3320-3331. PubMed ID: 31064850
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
8. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
9. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
10. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
11. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y
Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.
Wang Q; Bailey CG; Ng C; Tiffen J; Thoeng A; Minhas V; Lehman ML; Hendy SC; Buchanan G; Nelson CC; Rasko JE; Holst J
Cancer Res; 2011 Dec; 71(24):7525-36. PubMed ID: 22007000
[TBL] [Abstract][Full Text] [Related]
13. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
Zhou L; Zhang C; Yang X; Liu L; Hu J; Hou Y; Tao H; Sugimura H; Chen Z; Wang L; Chen K
Clin Transl Med; 2021 Jun; 11(6):e449. PubMed ID: 34185414
[TBL] [Abstract][Full Text] [Related]
14. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
15. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
16. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
17. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
Wang Q; Tiffen J; Bailey CG; Lehman ML; Ritchie W; Fazli L; Metierre C; Feng YJ; Li E; Gleave M; Buchanan G; Nelson CC; Rasko JE; Holst J
J Natl Cancer Inst; 2013 Oct; 105(19):1463-73. PubMed ID: 24052624
[TBL] [Abstract][Full Text] [Related]
18. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
19. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
20. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]